skip to content
Detailed Quote
5i Report
Rating
B

Review of Kneat.com

JUN 12, 2025 - KSI’s critical solutions to large pharmaceutical and biotech firms are highly sticky software. KSI’s customers not only tend to stay with KSI’s platform for the long term, but also expand spending over time. As a result, Annual Recurring Revenue (ARR) – a key performance indicator of SaaS business, which KSI consistently achieves strong growth over the years. In the most recent quarter, KSI reported a 51% growth in ARR. Also, KSI has started to demonstrate cost control discipline, as all expenses consisting of research and development (R&D), sales, and general and administrative (SG&A) expenses grew much slower than sales in recent quarters. We think the company could start to see some meaningful improvement in terms of profitability and cash flow over the coming years. KSI resembles some of the early compounders in the making. We think that if the management can continue to execute, the company could be a great long-term holding for growth-oriented investors. We are initiating our ratings at ‘B’.

Download Report
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Hi,
You’ve mentioned a lot of small caps that have already had significant growth in share price. What are some small cap names that have not yet landed on everyone’s radar?
Read Answer Asked by Ian on January 06, 2026
Q: I am down on these two companies in my TFSA, and am thinking of selling in favor of another Canadian growth company. I already own ELVA, FTG, GRID, KITS, PNG, VNP and ZDC. Which would you add to, or do you suggest adding another growth company.
Read Answer Asked by Merrilyn on December 12, 2025
Q: I have been holding KSI for months, and it has been trading sideways to down since my initial purchase. I have read through summaries of its last several quarterly reports, going back to Q1 2024, and it seems that the high-profile metrics (revenue, gross profit, EBITDA) are all consistently improving and trending in the right direction. Operating expenses increased in the most recent quarter, but it is my understanding that they did so because the company increased investments in R&D, along with sales and marketing.

In short, it seems to me that the company is making progress where it counts, and making moves to position it for further improvement. The market seems to be unhappy with the company. I am looking to increase my exposure to KSI, but I can't decide if my interpretation of results is accurate or wishful thinking. I only have about a 1% exposure to KSI, so doubling it (roughly what I would be putting into the investment) is not going to be a game-changer for me. Any thoughts here on whether I should add now, wait until further consolidation in price, or simply move onto another idea? As always, I appreciate what 5i provides, and I have referred many people to your service. It is worth the investment.
Read Answer Asked by Domenic on December 09, 2025
Insiders
Share Information
News and Media
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!